Massimo Milli

Massimo Milli

Auto-generated profile, based on publicly available information

Massimo Milli

Cardiologia Firenze 1 (Ospedali S. Maria Nuova e Nuovo San Giovanni di Dio), Azienda USL Toscana Centro , Firenze, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 May 2025 in European Heart Journal Supplements
Verified
Journal Article
Open access
CCCristina Chimenti
Cristina Chimenti
AIAttilio Iacovoni
Attilio Iacovoni
AMAndrea Montalto
Andrea Montalto
MEMichele Emdin
Michele Emdin
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
FOFabrizio Oliva
Fabrizio Oliva
Hypertrophic cardiomyopathy (HCM) is a non-rare genetic cardiomyopathy, with an estimated prevalence of 1:500, characterized by an increase in the left ventricular wall thickness in the absence of increased loading conditions. The hypertrophy is mostly asymmetric and predominantly affects the basal septum and anterior wall. Left ventricular outflow tract obstruction, at rest or after provocative tests, is detected in many patients and represents the primary cause of reduced functional capacity, as well as an independent predictor of sudden cardiac death and advanced heart failure. Until ∼1 year ago, symptomatic patients despite maximal therapy with β-blockers or calcium channel blockers plus disopyramide had only basal septal reduction therapy through myectomy or septal alcoholization as additional therapeutic options. Today, a new class of drugs that inhibit cardiac myosin activity is available for patients with obstructive HCM. In light of the new treatment perspectives, the correct clinical-therapeutic classification of affected patients becomes of fundamental importance for the cardiologist. The aim of this position paper is to increase the knowledge of cardiologists in the field of HCM, defining its epidemiological, genetic, and pathological characteristics, identifying the diagnostic criteria and instrumental methods capable of stratifying the risk profile, with the aim of an optimal therapy tailored on the single patient.

15 May 2025 in European Heart Journal Supplements
Verified
Journal Article
Open access
Leonardo De LucaLeonardo De Luca
Leonardo De Luca
Claudio BilatoClaudio Bilato
Claudio Bilato
ANAlessandro Navazio
Alessandro Navazio
MCMarco Corda
Marco Corda
MMMassimo Milli
Massimo Milli
FOFabrizio Oliva
Fabrizio Oliva
Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a pivotal therapeutic agent in the management of the cardio-renal-metabolic continuum. Initially developed for glycaemic control in Type 2 diabetes mellitus, its benefits extend far beyond glucose regulation. Clinical trials have demonstrated semaglutide’s potential to reduce major adverse cardiovascular events, particularly in overweight/obese patients with high cardiovascular risk, as well as improving functional capacity in patients suffering from heart failure with preserved left ventricular function. Additionally, it has shown promise in improving renal outcomes, such as slowing the progression of albuminuria and reducing the risk of chronic kidney disease in diabetic populations. These effects are likely due to its multifaceted mechanisms, including anti-inflammatory properties, weight reduction, blood pressure lowering, and direct renal protection. This review synthesizes current evidence on semaglutide’s role in the interrelated domains of cardiovascular, renal, and metabolic health.

15 May 2025 in European Heart Journal Supplements
Verified
Journal Article
Open access
SVSerafina Valente
Serafina Valente
PTPaolo Trambaiolo
Paolo Trambaiolo
GCGianni Casella
Gianni Casella
ASAlice Sacco
Alice Sacco
CDCarlotta Sorini Dini
Carlotta Sorini Dini
FOFabrizio Oliva
Fabrizio Oliva
Recently, intensive cardiac care units (ICCUs) have undergone a significant transformation related to the evolution in management of acute coronary syndrome and influenced by other factors such as the epidemiological transition, the increasing complexity of clinical cases, the technological advancement, and the growth of clinical and scientific expertise of cardiologists. In the context of this evolution, a functional reorganization of ICCUs in Italy has to be implemented in order to meet the changing needs of the population with cardiovascular disease requiring critical care. Therefore, the Italian Association of Hospital Cardiologists (ANMCO) proposes this position paper for the reorganization of CICUs into three levels with increasing functional complexity, based on the hospital characteristics, the available technology, and the clinical cases treated. The system would be functionally integrated into a regional ICCU organization modelled on a time-dependent care network. This proposed network aims to standardize diagnostic and therapeutic protocols and establish unified data collection registries to facilitate self-assessment and support clinical research. The document delineates specific requirements for each ICCU level, including the management of clinical cases, the expertise of intensive care cardiologists, the technological facilities, and the medical and nursing staff needed to ensure optimal care delivery.

7 May 2026 in European Heart Journal Supplements
Verified
Journal Article
Open access
FLFabiana Lucà
Fabiana Lucà
GGGian Franco Gensini
Gian Franco Gensini
FGFrancesco Gabbrielli
Francesco Gabbrielli
DADaniela Aschieri
Daniela Aschieri
MBMichela Barisone
Michela Barisone
MGMassimo Grimaldi
Massimo Grimaldi
The ongoing digital transformation is reshaping organisational and care delivery models in cardiology, positioning telemedicine as a pivotal tool to address increasing clinical and demographic complexity. This manuscript presents a comprehensive and critical overview of telemedicine applications in cardiovascular care, with a focus on its role in strengthening hospital-community integration, its deployment within hospital-based healthcare systems, and the associated regulatory and operational frameworks. The analysis encompasses the management of chronic cardiovascular conditions, such as heart failure and atrial fibrillation, through telemonitoring, telecontrol, televisit, and teleconsultation. Additionally, it explores the use of digital technologies in post-myocardial infarction follow-up, oral anticoagulation management, preoperative assessment, and care for elderly patients. The review also highlights the challenges and opportunities linked to digital infrastructure, interoperability, data protection, and healthcare professional training.

7 May 2026 in European Heart Journal Supplements
Verified
Journal Article
Open access
FLFabiana Lucà
Fabiana Lucà
EPEugenio Picano
Eugenio Picano
DADaniela Aschieri
Daniela Aschieri
IBIlaria Battistoni
Ilaria Battistoni
Claudio BilatoClaudio Bilato
Claudio Bilato
MGMassimo Grimaldi
Massimo Grimaldi
Interventional cardiology has profoundly transformed the management of cardiovascular disease; however, working within the cardiac catheterization laboratory exposes healthcare professionals to substantial occupational hazards. Four principal risks can be identified: (i) malignancy and non-malignant sequelae related to chronic exposure to ionizing radiation; (ii) musculoskeletal injury associated with prolonged use of heavy radioprotective equipment; (iii) exposure to blood-borne pathogens and other infectious agents; and (iv) work-related psychological strain. Among these, cumulative radiation exposure remains the most consequential and historically under-recognized threat. Although the radiation dose which operators receive during a single procedure is markedly lower than that delivered to patients, healthcare professionals are subjected to repeated, lifelong exposure. For a high-volume interventional cardiologist, the annual effective dose may substantially exceed that of other radiation-exposed professionals, including nuclear industry workers and diagnostic radiologists. Importantly, unlike radiologists, many cardiologists receive limited formal training in radiation physics and radiobiology, which may lead to limited awareness of dose-optimization strategies and stochastic risk. Contemporary epidemiological evidence has refined our understanding of the biological effects of chronic low-dose and low-dose-rate radiation. Risk estimates for malignancy have progressively increased as follow-up durations have lengthened and methodological approaches have improved. Moreover, emerging data suggest that sustained low-dose exposure may confer an elevated risk of cardiovascular disease, thereby extending concern beyond oncological endpoints. Occupational exposure varies greatly depending on the location: doses to the head can be several times higher than doses to the chest, with a predominance on the left side attributable to the position of the operator in relation to the X-ray source. In addition to the well-established association with posterior subcapsular cataracts, observational studies have reported potential links between long-term occupational exposure and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, although causality remains to be definitively established. Mitigation of these risks necessitates a paradigm shift towards a rigorous culture of radiation safety. Institutional commitment is essential, encompassing advanced shielding systems, ceiling-suspended protection, real-time dosimetry with immediate feedback, and systematic optimization of imaging protocols. Ultimately, the future of the field may depend on the progressive adoption of radiation-sparing and radiation-free technologies, including intracardiac and intracoronary ultrasound, electro anatomical mapping systems, and non-fluoroscopic navigation platforms. In parallel, robot-assisted procedures enable remote manipulation of the catheter promise to reduce the operator's direct exposure. The pursuit of a zero-radiation environment in the workplace should not be considered an ambitious ideal but a strategic priority to safeguard the next generation of interventional cardiologists.